Table 3.

Associations between tumor marker expression and clinical stage and extranodal involvement: HIV-related DLBCL

Marker positivity	cMYC		P27		BCL6		PKC-β2		MUM1		CD44
	−	+	−	+	−	+	−	+	−	+	−	+
	n = 25	n = 45	n = 45	n = 29	n = 40	n = 23	n = 28	n = 44	n = 33	n = 43	n = 10	n = 65
Stage	Column percent (% of stage within subgroups defined by marker positivity)
Localized	25.0%	26.2%	36.8%	17.9%	50.0%	50.0%	29.6%	24.3%	27.6%	25.6%	30.0%	26.3%
Regional	25.0%	16.7%	15.8%	21.4%	10.8%	27.6%	22.2%	16.2%	17.2%	20.5%	30.0%	15.8%
Distant	50.0%	57.1%	47.4%	60.7%	64.9%	41.4%	48.2%	59.5%	55.2%	53.9%	40.0%	57.9%
P value	0.73		0.24		0.11		0.66		0.94		0.47
Extranodal involvement	Column percent (% of extranodal involvement within subgroups defined by marker positivity)
Yes	48.0%	42.2%	33.3%	58.6%	52.5%	30.3%	50.0%	40.9%	39.4%	44.2%	40.0%	43.1%
P value	0.64		0.03		0.06		0.45		0.67		0.85